Clinical Characteristics, MRI Findings, Disease Progression, and Management of Neuro-Behçet’s Disease: A Retrospective Study in Lebanon

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(8), P. 2543 - 2543

Published: April 8, 2025

Background: Behçet’s Disease (BD) is a complex vasculitis affecting multiple organ systems, with Neuro-Behçet’s (NBD) representing rare yet severe manifestation. Data on NBD are limited, particularly in Middle Eastern populations. Methods: This retrospective observational study, spanning from 2000 to 2021, involved 262 BD patients at tertiary medical center Lebanon. was diagnosed based International Consensus Recommendation diagnostic criteria. Clinical data, including demographics, manifestations, inflammatory blood markers, genetics, and treatments, were collected. The modified Rankin Scale (mRS) used assess disease severity. Results: Among the cohort, 27 (10.3%) had NBD, headaches, weakness, dizziness as most common presenting symptoms. prevalence of similar across genders, which differs some regional studies. HLA-B51 positivity found 50 out 60 (83.3%) tested patients. Parenchymal cases exhibited greater severity than non-parenchymal cases, female experiencing more course compared males. Elevated markers (CRP ESR) NBD. Corticosteroids colchicine commonly therapies overall, while better frequently prescribed methotrexate, mycophenolate, cyclophosphamide, adalimumab, rituximab. An analysis progression showed that presentation, 57.1% (n = 12) mild moderate disability, increased 76.2% 16) last follow-up, 10 who an improvement their mRS score. Conclusions: study provides valuable insights into clinical characteristics population. These findings enhance our understanding East, highlighting need for further research improve diagnosis management.

Language: Английский

Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions

Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. e00588 - e00588

Published: April 1, 2025

Multiple sclerosis (MS) is a complex, chronic immune-mediated disease characterized by acute and progressive inflammatory damage of the central nervous system. MS manifests clinically with unpredictable neurological symptoms from focal attacks as well gradual neurodegeneration which contribute significantly to long-term disability progression. As treatment options advance, developing more personalized strategies capture heterogeneous mechanisms injury may be targeted or predict outcomes has been focus ongoing investigation. The role soluble biomarkers emerged pivotal tool assist in these goals. Early promising candidates include neurofilament light chain (NfL) glial fibrillary acidic protein (GFAP); intermediate filaments that are expressed neurons astrocytes, respectively, reliably measurable blood samples can reveal clinical subclinical changes, Changes indicate response therapy, thus potentially used endpoints trials. Furthermore, recent research identified potential other neuroimmunological conditions including neuromyelitis spectrum disorder (NMOSD) myelin oligodendrocyte glycoprotein associated (MOGAD), autoimmune encephalitis, neurosarcoidosis, neuropsychiatric involvement connective tissue disorders vasculitides, host neurodegenerative conditions. By integrating biomarker analysis into routine assessments, healthcare providers move toward nuanced individualized care model, better equipped meet challenges posed multifaceted diseases. Understanding dynamics many applications improve medicine MS.

Language: Английский

Low IL-35 Expression in CSF is Associated with Neuro-Behcet Disease: Comparative Analysis Between Parenchymal and Non-Parenchymal NBD

Immunology Letters, Journal Year: 2025, Volume and Issue: unknown, P. 107031 - 107031

Published: May 1, 2025

Language: Английский